Author

Francis Baumgartner

Observed names: Baumgartner, Francis, F. Baumgartner

Institutions: The University of Melbourne, Peter MacCallum Cancer Centre, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charité - Universitätsmedizin Berlin

Observed institutions: University of Freiburg, The University of Melbourne, German Cancer Research Center, Max Delbrück Center, Peter MacCallum Cancer Centre, University Medical Center Freiburg, Humboldt-Universität zu Berlin, Munich Leukemia Laboratory (Germany), Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Deutsches Konsortium für Translationale Krebsforschung, Freie Universität Berlin, Charité - Universitätsmedizin Berlin

ORCID: 0000-0003-0768-1956

Observed ORCID: 0000-0003-0768-1956

OpenAlex ID: A5059762155

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

2018 · Nimitha R Mathew, Francis Baumgartner, et al. · Nature Medicine · 295

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer

2022 · Uta M. Demel, Marlitt Böger, et al. · Journal of Clinical Investigation · 86

SNAIL1 combines competitive displacement of ASCL2 and epigenetic mechanisms to rapidly silence the EPHB3 tumor suppressor in colorectal cancer

2014 · Kerstin Rönsch, Sabine Jägle, et al. · Molecular Oncology · 43

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

2022 · Guus J. J. E. Heynen, Francis Baumgartner, et al. · Blood Advances · 32

Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022

2023 · Francis Baumgartner, Constance Baer, et al. · Blood · 25

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

2018 · Nimitha R Mathew, Francis Baumgartner, et al. · Nature Medicine · 12

Activation of gp130 signaling in T cells drives T H 17-mediated multi-organ autoimmunity

2024 · Francis Baumgartner, Stefanos A. Bamopoulos, et al. · Science Signaling · 8

Sorafenib Promotes Graft-Versus-Leukemia Activity in Mice and Humans through IL-15 Production in Leukemia Cells

2016 · Nimitha Rose Mathew, Francis Baumgartner, et al. · Transplantation and Cellular Therapy · 4

The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2025 · Kaiting Jiang, Marieluise Kirchner, et al. · Molecular Cancer Therapeutics · 1

A Unified Post-Transcriptional Mechanism Regulates Intron Retention in Splicing Factor-Mutant MDS

2024 · Prajwal Boddu, Rahul Roy, et al. · Blood · 1

P855: Synergistic Efficacy of Combined Sumoylation and Proteasome Inhibition in Multiple Myeloma

2022 · U. Keller, G. Heynen, et al. · HemaSphere · 1

CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy

2026 · Francis Baumgartner, Michael J. Dickinson, et al. · Blood

Activating somatic EPOR mutation in primary erythrocytosis

2026 · Francis Baumgartner, Ali Khalil, et al. · Pathology

Supplementary Table 1 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Figure 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Data 1 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Data from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Figure 7 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Figure 9 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Figure 1 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Data 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Figure 2 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Figure 8 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Figure 5 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Supplementary Data 3 from The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma

2026 · Kaiting Jiang, Marieluise Kirchner, et al.

Works count: 33

Citation count: 508

H-index: 7

I10-index: 6